Ultragenyx Pharmaceutical Inc (MEX:RARE)
MXN 751.98 0 (0%) Market Cap: 65.87 Bil Enterprise Value: 59.05 Bil PE Ratio: 0 PB Ratio: 23.46 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 14, 2021 / 08:15PM GMT
Release Date Price: MXN2008.83
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst

Welcome to the Morgan Stanley Global Healthcare Conference. I'm Jeff Hung, one of the biotech analysts. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have Emil Kakkis, CEO of Ultragenyx. Welcome, Emil.

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - President, CEO & Director

Thank you.

Questions & Answers

Jeff Hung
Morgan Stanley, Research Division - Equity Analyst

For those who may not be familiar with Ultragenyx, can you provide a brief introduction?

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - President, CEO & Director

Sure. I can give you just a few minute snapshot. Ultragenyx is a company focused on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot